ArticleTissue engineering and regenerative medicine2026
Combining Surface Modification and Bioactive Cues to Enhance Medpor® Implant Integration In Vivo.
Article in Tissue engineering and regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAchieving stable and functional integration of synthetic implants with host tissue remains a key challenge in tissue engineering. Medpor®, a porous high-density polyethylene (HDPE) implant widely used in craniofacial reconstruction, provides excellent mechanical strength but lacks bioactivity, limiting early cell adhesion, vascularization, and extracellular matrix (ECM) deposition.
methodsTo enhance Medpor® biointegration, we employed a multi-faceted modification strategy combining plasma treatment with biologically active components. Treated implants were coated with collagen and fibrin hydrogels and further supplemented with a platelet-derived Purified Exosome Product (PEP). Modified and control implants were evaluated in a subcutaneous mouse model to assess host tissue response, vascularization, and implant integration.
resultsTissue ingrowth was observed in the pores of all Medpor® implants. Plasma treatment significantly increased the surface hydrophilicity of Medpor®, promoting host cell adhesion and tissue infiltration. Implants modified with both hydrogels and PEP exhibited enhanced ECM deposition, greater vascular density, and improved tissue integration compared to untreated Medpor®. The combination of physicochemical surface treatment and biochemical cues led to a synergistic effect, supporting tissue ingrowth and angiogenesis under a controlled host immune response.
conclusionThis study demonstrates that integrating plasma surface modification with bioactive hydrogels and PEP can effectively enhance the biointegration of Medpor® implants in vivo. The combined approach significantly enhances implant vascularization and ECM development, offering a promising translational strategy for improving synthetic implant performance in regenerative and reconstructive biomaterial applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.